GlucoTrack, Inc. (GCTK)
Nasdaq · Healthcare · Medical Devices
$1.11−8.26%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1M
- 52-week range
- $1.10 – $136.29
- 52-week change
- −98.89%
- EPS (trailing)
- −$123.15
Fiscal year to Dec 2025
- Net income
- −$19.4M
- Diluted EPS
- $31.22
- Free cash flow
- −$15.3M
From the company’s annual report on SEC EDGAR.
About GlucoTrack, Inc.
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Headquarters: Rutherford, United States · 15 employees · glucotrack.com